Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer

Cancer

Volumn 117, Issue 20, 2011, Pages 4623-4632

  Tran, Ben ^a   Kopetz, Scott ^b   Tie, Jeanne ^c   Gibbs, Peter ^c,d   Jiang, Zhi Qin ^b   Lieu, Christopher H ^b   Agarwal, Atin ^b   Maru, Dipen M ^b   Sieber, Oliver ^c,d   Desai, Jayesh ^c,d  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF TEXAS   (United States)

^c OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^d BioGrid Australia   (Australia)

Author keywords

BRAF; colorectal cancer; metastases; microsatellite instability; survival

Indexed keywords

B RAF KINASE;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MICROSATELLITE INSTABILITY; MUTATION; OVERALL SURVIVAL; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROGNOSIS;

AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 79958817037     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26086     Document Type: Article

References (28)

1. Weitz J, Koch M, Debus J, et al. Colorectal cancer. The Lancet. 2005; 365: 153-165. (Pubitemid 40091806)
2. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009; 27: 3677-3683.
3. Tie J, Gibbs P, Lipton L, et al. Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int J Cancer. 2011;128:2075-2084.
4. Van Cutsem E, Kohne C-H, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360: 1408-1417.
5. Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol. 2009; 27: 5924-5930.
6. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008; 26: 5705-5712.
7. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to antiepidermal growth factor receptor antibody therapies. Cancer Res. 2007; 67: 2643-2648. (Pubitemid 46548951)
8. Tol J, Nagtegaal ID, Punt CJA,. BRAF mutation in metastatic colorectal cancer. N Engl J Med. 2009; 361: 98-99.
9. Souglakos J, Philips J, Wang R, et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer. 2009; 101: 465-472.
10. Richman SD, Seymour MT, Chambers P, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol. 2009; 27: 5931-5937.
11. Muller CI, Schulmann K, Reinacher-Schick A, et al. Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group. Int J Colorectal Dis. 2008; 23: 1033-1039.
12. Popat S, Hubner R, Houlston RS,. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005; 23: 609-618. (Pubitemid 46224239)
13. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783-792. (Pubitemid 32222155)
14. Leyland-Jones B,. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol. 2009; 27: 5278-5286.
15. Kopetz S, Desai J, Chan E, et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors [abstract]. J Clin Oncol. 2010; 28 (15 suppl). Abstract 3534.
16. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010; 28: 3219-3226.
17. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008; 26: 5705-5712.
18. Li WQ, Kawakami K, Ruszkiewicz A, et al. BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer. 2006; 5: 2.
19. Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009; 58: 90-96.
20. Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005; 65: 6063-6069.
21. Assersohn L, Norman A, Cunningham D, et al. Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma. Br J Cancer. 1999; 79: 1800-1805. (Pubitemid 29132308)
22. Wang L, Cunningham JM, Winters JL, et al. Advances in brief BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair 1. Cancer Res. 2003; 63: 5209-5212. (Pubitemid 37139829)
23. Benedix F, Kube R, Meyer F, et al. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum. 2010; 53: 57-64.
24. Catalano V, Loupakis F, Graziano F, et al. Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy. Br J Cancer. 2009; 100: 881-887.
25. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003; 349: 247-257. (Pubitemid 36859476)
26. Chen WS, Chen JY, Liu JM, et al. Microsatellite instability in sporadic-colon-cancer patients with and without liver metastases. Int J Cancer. 1997; 74: 470-474. (Pubitemid 27400172)
27. Des Guetz G, Uzzan B, Nicolas P, Schischmanoff O, Morere J-F,. Microsatellite instability: a predictive marker in metastatic colorectal cancer? Target Oncol. 2009; 4: 57-62.
28. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010; 28: 466-474.